According to Latest Market research report Published by MarketsandMarkets the “HPV Testing and Pap Test Market Size, Share, Demand and Growth Analysis, forecast” the Global Market is expected to reach $ 4.52 billion, at a CAGR of 6.6%
The HPV test is used to diagnose the infection caused by HPV that mutates a normal cell into a cancerous cell and further leads to the development of genital warts, abnormal cervical cells, or cervical cancer. The growth of the HPV testing and Pap test market is mainly attributed to the increasing number of cervical cancer cases, growing the aging population, increasing awareness of cervical cancer screening programs, and government initiatives and funding
key players operating in the Global HPV Testing and Pap Test Market;
Key players in the market include Hologic Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (U.S.), OncoHealth Corporation (U.S.), and Becton, Dickinson and Company (U.S.)
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=214207371
Major Dynamics Impacting the HPV Testing and Pap Test Market;
· Growth Drivers:
1. An increasing number of cervical cancer cases and a growing aging population
2. Increasing awareness of cervical cancer screening programs
3. Government initiatives and funding.
· Restraints
- Changes in regulatory guidelines for cervical cancer screening
- HPV vaccination
Objectives of The Study-
- To analyze micro-markets with respect to individual growth trends, prospects, and contributions to the global HPV testing and Pap test market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market players
- To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
Request Research Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371
Major Market Developments-
- In September 2015, QIAGEN introduced the careHPV Test and Digene HC2 Collection Device for the HPV screening process in women.
- IN February 2014, QIAGEN expanded commercial launch of the careHPV test in India, a molecular diagnostic test for high-risk human papillomavirus (HPV), a primary cause of cervical cancer in woman.
Global HPV Testing and Pap Test Market Segmentation:
Based on end user, the HPV testing and Pap test market are categorized into hospitals, laboratories, physician’s offices, and clinics. The hospital's segment is projected to grow at the highest CAGR. This growth is attributed to the increasing patient volumes in hospitals, as most diagnostic tests are carried out in-house with advanced technologies and more accessibility.
Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to grow at the highest CAGR in the forecast period. Increased government funding & grants and introduction of HPV primary tests are major factors fueling the growth of the HPV testing and Pap test market in North America.
